Close Menu

NEW YORK – Credo Diagnostics Biomedical announced Friday its combination VitaPCR Influenza A&B/SARS-CoV-2 test received CE-IVD marking. 

The point-of-care RT-PCR test delivers results from one nasopharyngeal sample in 20 minutes and can be used on the firm's VitaPCR instrument. The platform can perform 24 runs per day with one sample per run and doesn't need "highly trained personnel," Credo said in a presentation on the test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.